Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/24/2025

Hypertensive Urgency Management

Definition and Diagnosis

  • Hypertensive urgency is defined as severe blood pressure elevation (typically >180/120 mmHg) without evidence of acute target organ damage 1
  • This condition differs from hypertensive emergency, which involves the same BP elevation but with evidence of new or worsening target organ damage 1

Medication Selection and Dosage

  • Labetalol is the preferred first-line medication due to its combined alpha and beta-blocking properties, predictable response, and safety profile 1, 2
  • The initial dosing for labetalol is 0.3-1.0 mg/kg dose (maximum 20 mg) as slow IV injection every 10 min or 0.4-1.0 mg/kg/h IV infusion up to 3 mg/kg/h 3, 4
  • Nicardipine dosing starts at 5 mg/h, increasing every 5 min by 2.5 mg/h to a maximum of 15 mg/h 1
  • Clevidipine dosing starts at 1-2 mg/h, doubling every 90 seconds until BP approaches target 1
  • Esmolol dosing involves a loading dose of 500-1000 mcg/kg/min over 1 min followed by 50 mcg/kg/min infusion 3
  • Fenoldopam dosing starts at 0.1-0.3 mcg/kg/min, may be increased in increments of 0.05-0.1 mcg/kg/min every 15 min 3

Blood Pressure Reduction Goals

  • For hypertensive urgency, SBP should be reduced by no more than 25% within the first hour 1
  • Then, if stable, to 160/100 mmHg within the next 2-6 hours 1
  • Finally, cautiously to normal during the following 24-48 hours 1

Special Considerations

  • Avoid rapid BP reduction as it can lead to organ hypoperfusion, particularly cerebral hypoperfusion 1
  • Medication selection should be based on patient comorbidities, such as acute coronary syndromes, acute pulmonary edema, acute renal failure, catecholamine excess states, and eclampsia/preeclampsia 6

Medication Contraindications

  • Labetalol is contraindicated in patients with reactive airways disease, COPD, heart failure, second or third-degree heart block, and bradycardia 3, 4
  • Esmolol is contraindicated in patients with concurrent beta-blocker therapy, bradycardia, and decompensated heart failure 3
  • Fenoldopam is contraindicated in patients with increased intraocular pressure, glaucoma, and sulfite allergy 3